ANTIBIOTIC RESISTANCE: THE ROLE OF SYSTEMIC MECHANISMS OF THE MACROORGANISM AND THEIR ABILITY TO DETERMINE THE INSUFFICIENT EFFECTIVENESS OF DRUGS (LITERATURE REVIEW)
Main Article Content
Abstract
Modern medicine is faced with one of the most serious threats to human health – antibiotic resistance. According to the World Health Organization (WHO), by 2050, antibiotic resistance in microorganisms could cause more than 10 million deaths annually, surpassing even cancer in terms of its consequences [World Health Organization (WHO), 2019].
This phenomenon not only undermines the effectiveness of modern antibiotic therapy, but also threatens advances in the treatment of infectious diseases, surgery, pediatrics, and other areas of medicine where antibacterial drugs play a key role.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Shankaran H, Wiley HS, Resat H. Receptor downregulation and desensitization enhance the information processing ability of signalling receptors. BMC Syst Biol. 2007; 1: 48. doi: 10.1186/1752-0509-1-48
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414(6865): 799-806. doi: 10.1038/414799a
Chiang SH, Baumann CA, Kanzaki M, Thurmond DC, Watson RT, Neudauer CL, et al. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature. 2001; 410(6831): 944-948. doi: 10.1038/35073608
Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr. 2001; 33(6): 453-458. doi: 10.1023/a:1012866803188
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3): 219-234. doi: 10.1038/nrd1984
Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A. 2011; 108(46): 18708-18713. doi: 10.1073/pnas.1111840108
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1): 103-141. doi: 10.1016/j.pharmthera.2012.12.007
Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 2008; 21(1): 70-83. doi: 10.1021/tx700079z
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004; 32(11): 1201-1208. doi: 10.1124/dmd.104.000794
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther. 2001; 69(6): 400-406. doi: 10.1067/mcp.2001.115822
Josephy PD. Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. Hum Genomics Proteomics. 2010; 2010: 876940. doi: 10.4061/2010/876940
Hansten PD, Horn JR. Drug Interactions: Analysis and Management [Электронный ресурс]. 2nd ed. St. Louis: Facts and Comparisons, 2003. Режим доступа: https://openlibrary.org/books/OL9402710M/Drug_Interactions_Analysis_and_Management , свободный
Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013; 13(5): 331-342. doi: 10.1007/s40256-013-0029-0
Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. Clin Rev Allergy Immunol. 2007; 30(1): 5-15. doi: 10.1159/000104199
Warrington R, Watson W, Kim HL, Antonetti FR. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2011; 7 Suppl 1(Suppl 1): S1. doi: 10.1186/1710-1492-7-S1-S1
Nicolaides NC, Charmandari E. Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. Hormones. 2017; 16: 124-138. doi: 10.14310/horm.2002.1728
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005; 5(1): 6-13. doi: 10.1038/sj.tpj.6500285
Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. New Engl J Med. 2003; 348(6): 538-549. doi:10.1056/NEJMra020526
Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007; 128(4): 635-638. doi: 10.1016/j.cell.2007.02.006
Peng L, Zhong X. Epigenetic regulation of drug metabolism and transport. Acta Pharm Sin B. 2015; 5(2): 106-112. doi: 10.1016/j.apsb.2015.01.007
Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358(11): 1148-1159. doi: 10.1056/NEJMra072067
Wilson CG. Physiological factors affecting drug absorption. Expert Opinion on Drug Delivery. 2008; 15(5): 457-470. doi: 10.1517/17425247.5.5.457
Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010; 9(12): 929-939. doi: 10.1038/nrd3287
Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet. 1991; 338(8781): 1488-1490. doi: 10.1016/0140-6736(91)92302-i
Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2010. 772 p.
LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008; 11(1-2): 32-50. doi: 10.1016/j.drup.2007.11.003
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39(1): 44-84. doi: 10.1016/j.biocel.2006.07.001